Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023


Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 am ET.

The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise's platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company's lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2i muscular dystrophies, and McArdle's disease. The Company is also advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.


These press releases may also interest you

at 08:35
NanoVibronix, Inc. ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

at 08:34
Kruze Consulting, the startup accounting and CFO consulting firm servicing more than 800 venture funded startup clients, has released new data on how startups have changed their banking strategies a year after the SVB collapse. According to the data,...

at 08:34
RapidVerify, a provider of identity verification solutions, today announced it has become an authorized E-Verify Employer Agent. This designation underscores RapidVerify's commitment to streamlined and reliable employment eligibility verification for...

at 08:33
Tiger Group is offering for immediate purchase unused packaging and labeling equipment from a shuttered pharmaceutical company. "These useful machines are a great fit for a wide array of industries?not just pharmaceutical and medical but also food...



News published on and distributed by: